From: The content validity of the PSS in patients with plaque psoriasis
Total Sample (N = 20) | |
---|---|
Time Since Psoriasis Diagnosis, years | |
Mean ± SD | 17.9 ± 9.9 |
Median (IQR) | 19.6 (11.1–24.1) |
Range (Min – Max) | (0.2–38.6) |
Time on Systemic Treatment, years | |
Mean ± SD | 4.4 ± 4.8 |
Median (IQR) | 2.3 (1.4–7.0) |
Range (Min – Max) | (0.1–20.0) |
Comorbidities, n (%) | |
Anxiety | 2 (10%) |
Depression | 2 (10%) |
Psoriatic Arthritis | 4 (20%) |
Othera | 12 (60%) |
No other health conditions | 8 (40%) |
Current treatmentsb, n (%) | |
Secukinumab | 1 (5%) |
Etanercept | 3 (15%) |
Folic Acid | 1 (5%) |
Adalimumab | 4 (20%) |
Ixekizumab | 4 (20%) |
Methotrexate | 1 (5%) |
Ustekinumab | 5 (25%) |
Ultraviolet B (shortwave) Waves (UVB) | 2 (10%) |
Other | 1 (5%) |